BGLCNasdaqServices-Medical LaboratoriesFiscal year ends December 31
BioNexus Gene Lab Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.23+0.03 (+2.23%)
Close on Oct 19, 2026
- Market cap
- $2.97M
- P/E (TTM)
- –
- Dividend yield
- –
BioNexus Gene Lab statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Services-Medical Laboratories companies for comparison
Valuation
| Measure | BioNexus Gene Lab | Industry median |
|---|---|---|
| Market Cap | $3.60M | $1.11B |
| Enterprise Value | $2.37M | $1.41B |
| PS Ratio | 1.15 | 1.60 |
| PB Ratio | 0.46 | 3.03 |
| P/TBV Ratio | 0.46 | 4.99 |
Enterprise value
| Measure | BioNexus Gene Lab | Industry median |
|---|---|---|
| EV / Sales | 0.76 | 1.69 |
Income (trailing twelve months)
| Measure | BioNexus Gene Lab | Industry median |
|---|---|---|
| Revenue | $3.13M | $561.90M |
| Gross Profit | $385.89K | $173.32M |
| Operating Income | -$2.56M | -$1.81M |
| Pretax Income | -$2.58M | -$572.42K |
| Net Income | -$2.58M | -$1.16M |
| EBITDA | -$2.56M | -$20.72K |
Margins
| Measure | BioNexus Gene Lab | Industry median |
|---|---|---|
| Gross Margin | 12.3% | 33.1% |
| Operating Margin | -81.8% | -4.45% |
| Pretax Margin | -82.4% | 1.54% |
| Profit Margin | -82.4% | -2.91% |
| EBITDA Margin | -81.8% | 2.41% |
| FCF Margin | -27.3% | 3.13% |
Returns
| Measure | BioNexus Gene Lab | Industry median |
|---|---|---|
| Return on Equity (ROE) | -33.7% | 1.84% |
| Return on Assets (ROA) | -28.4% | -3.06% |
| Return on Invested Capital (ROIC) | -32.3% | 2.11% |
| Return on Capital Employed (ROCE) | -32.3% | -0.57% |
Growth
| Measure | BioNexus Gene Lab | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -67.3% | 6.92% |
| Revenue Growth (3Y CAGR) | -12.1% | 10.9% |
| Revenue Growth (5Y CAGR) | -8.20% | 13.2% |
Balance sheet
| Measure | BioNexus Gene Lab | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $1.23M | $48.71M |
| Net Cash (Debt) | $1.23M | $205.49K |
| Net Cash Per Share | $0.42 | $0.01 |
| Equity (Book Value) | $7.78M | $235.16M |
| Book Value Per Share | $2.65 | $3.48 |
| Tangible Book Value | $7.78M | $703.69K |
| Working Capital | $4.13M | $30.48M |
Financial position
| Measure | BioNexus Gene Lab | Industry median |
|---|---|---|
| Current Ratio | 6.08 | 1.40 |
| Quick Ratio | 1.54 | 1.02 |
Cash flow (trailing twelve months)
| Measure | BioNexus Gene Lab | Industry median |
|---|---|---|
| Operating Cash Flow | -$846.57K | $3.10M |
| Capital Expenditures | -$7.04K | -$18.62M |
| Free Cash Flow | -$853.60K | $23.73M |
| FCF Per Share | -$0.29 | $0.37 |
Efficiency
| Measure | BioNexus Gene Lab | Industry median |
|---|---|---|
| Asset Turnover | 0.34 | 0.87 |
| Inventory Turnover | 2.93 | 11.67 |
| Revenue Per Employee | $521.10K | $228.48K |
| Profits Per Employee | -$429.19K | -$5.75K |
| Employee Count | 6 | 910 |
Dividends and yields
| Measure | BioNexus Gene Lab | Industry median |
|---|---|---|
| Earnings Yield | -71.5% | -0.59% |
| FCF Yield | -23.7% | 1.74% |
Shares
| Measure | BioNexus Gene Lab | Industry median |
|---|---|---|
| Shares Outstanding | 2,933,440 | 58,282,400 |
| Shares Change (QoQ) | 0.00% | 0.32% |
| Float | 2,416,050 | 33,780,100 |
| Shares Held by Insiders | 17.6% | 16.4% |
| Shares Held by Institutions | 0.49% | 85.9% |
Taxes
| Measure | BioNexus Gene Lab | Industry median |
|---|---|---|
| Income Tax | $0 | $697.00K |
Scores
| Measure | BioNexus Gene Lab | Industry median |
|---|---|---|
| Altman Z-Score | 1.07 | 2.05 |
| Piotroski F-Score | 4 | 5 |
Calculated by StockData from BioNexus Gene Lab's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.